

New Drug Manufacturer Report

Section	Data element	Field type	Drug #1	Please add columns as needed
1. Drug identification	National drug code (11-digit NDC)	Numeric	72572-0067-10	
	Drug name	Text	Cisatracurium Besylate Intravenous Solution 200 MG/20ML 10 Vials	
2. Drug Launch Information	Description of the marketing and pricing plans used in the launch of the new drug in the United States and internationally	Text	<p>Civica selects products (including Cisatracurium Besylate) that are identified and prioritized by Civica's member health systems - by doctors and pharmacists on the front lines - as the medications most important for quality patient care. Each Civica member health system has the option to make a long-term commitment to purchase Cisatracurium from Civica by executing a Purchase Commitment Form. The Purchase Commitment Form contains the required duration of the purchase commitment and the expected annual minimum volume purchase commitment for each participating member (based on the member's historical pro rata usage volume relative to the other members).</p> <p>Civica sets a single, transparent price per Cisatracurium Besylate product for each of its members, regardless of the volume purchased. Civica sets its Cisatracurium Besylate prices at approximately cost plus a margin to cover Civica's overhead and research and development expenses.</p>	
	Estimated volume of patients who may be prescribed the drug	Numeric	Data is not available	
	Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval	Text	No	
	Date and price of acquisition if the drug was not developed by the manufacturer	Text	Civica is selling under a product supply agreement under the manufacturer. There was no licensing fee, or acquisition price, only a fee per unit purchased from the manufacturer	